ObjectivesTo systematically review the efficacy and safety of Shenlingbaizhusan as adjuvant therapy for gastric cancer.MethodsPubMed, EMbase, The Cochrane Library, CNKI, WanFang Data, VIP and CBM databases were electronically searched to collect randomized controlled trials (RCTs) on efficacy and safety of Shenlingbaizhusan as adjuvant therapy for gastric cancer from inception to July 31st, 2018. Two reviewers independently screened literature, extracted data and assessed risk of bias of included studies, then, meta-analysis was performed by using RevMan 5.3 software.ResultsA total of 14 RCTs involving 1 142 patients were included. The results of meta-analysis showed that: compared with control group, Shenlingbaizhusan could improve the efficiency of gastric cancer patients (RR=1.55, 95%CI 1.31 to 1.84, P<0.000 01) and the living quality of patients (RR=1.70, 95%CI 1.39 to 2.07, P<0.000 01), and reduce the side effects such as nausea, vomiting, diarrhea and the the possibilities of recurrence. However there was no difference between two groups in bone marrow suppression.ConclusionsThe current evidence shows that Shenlingbaizhusan as adjuvant therapy has better curative effect on gastric cancer, which can improve the efficiency of treatment and quality of life, and reduce some adverse reactions of chemotherapy. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusions.